<DOC>
	<DOCNO>NCT00848211</DOCNO>
	<brief_summary>This protocol represent first human study TUTI-16 , conduct establish safety human immunogenicity ( anti-HIV-1 Tat titer ) subcutaneously administer TUTI-16 . Activity TUTI-16 also determine minimize HIV-1 viral load sustain CD4+ T-cell level .</brief_summary>
	<brief_title>Clinical Study TUTI-16 Asymptomatic HIV-1 Infected Subjects</brief_title>
	<detailed_description>HIV-1 Tat protein , virally encode toxin , secrete HIV-1 infected cell act uninfected cell , render permissive HIV-1 replication . HIV-1 Tat enhance chronic viral replication induces immune suppression . Antibodies Tat inhibit Tat-mediated transcellular activation vitro minimize chronic plasma viremia . HIV-1 Tat activity block vitro vivo anti-Tat antibody . The Thymon Universal Tat Immunogen ( TUTI-16 ) fully synthetic , self-adjuvanting lipopeptide vaccine water soluble administer subcutaneous injection . In preclinical study , prim dose three week boost rat induce high titer antibody response eight know distinct epitope variant HIV-1 Tat protein . These antibody block function HIV-1 Tat protein ( toxin ) , essential maintenance chronic HIV-1 viremia . Therefore , TUTI-16 potential therapeutic vaccine HIV-1 human .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Males Females Age ≥18 ≤50 year Screening HIV1 seropositive asymptomatic generally good health prior antiretroviral therapy within 6 month screen viral load ≥ 3,000 ≤ 100,000 HIV1 RNA copies/mL CD4+ Tcell count ≥ 400/mm3 . Pregnant/nursing female positive HBV HCV acute Herpetic event clinically significant outof range laboratory value subject unable unwilling discontinue study participation another investigational drug/vaccine study within 30 day precede first injection investigational agent study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>HIV</keyword>
	<keyword>vaccine</keyword>
	<keyword>lipopeptide</keyword>
	<keyword>Tat</keyword>
	<keyword>TUTI-16</keyword>
	<keyword>THYMON</keyword>
	<keyword>Treatment Naive</keyword>
</DOC>